Lv52
1322 积分 2022-01-22 加入
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
16天前
已完结
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
16天前
已完结
关于我国病理质控工作的思考
16天前
已完结
SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant
18天前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
23天前
已完结
Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer
23天前
已完结
Autonomous biomedical research with an artificial intelligence agent
1个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
1个月前
已完结
The HER family as therapeutic targets in colorectal cancer
1个月前
已完结
The oncogenic EGFR-SHC1 fusion confers insensitivity to EGFR-TKI via dual activation of N-EGFR kinase domain and C-SHC1 phosphorylation sites in lung cancer
1个月前
已完结
皖公网安备34019202002308
